We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

News   Aug 01, 2018 | Original story from the National Institute of Standards and Technology (NIST)

 
New Cell Lines Produce NIST Monoclonal Antibody for Improved Biologic Drug Manufacturing

HeLa cancer cells appear green wherever mouse monoclonal antibodies (mAb) have bound to tubulin, a structural protein important in cell division. Binding to tubulin and preventing cell growth is one way that mAb drugs could kill tumors—the type of research that may benefit from the use of NIST's monoclonal antibody reference material, NISTmAb. Credit: ©EnCor Biotechnology Inc.

 
 
 

RELATED ARTICLES

Device Would Allow TB Dosing to Switch From Daily to Monthly

News

A drug delivery device is under development, which works by slowly releasing antibiotics directly into the patient's stomach. This would allow patients to switch from daily to monthly doses, reducing the burden of tuberculosis treatment.

READ MORE

Response to Skin Fungi Pivotal in Dermatitis Pathway

News

How does the immune system respond to fungi on our skin? Researchers at the University of Zurich have demonstrated that the same immune cells that protect us against skin fungi also encourage the inflammatory symptoms of atopic dermatitis. An antibody therapy could alleviate this chronic inflammatory skin disease.

READ MORE

Absorbable Antibiotic Envelope Can Cut Cardiac Device Infections

News

An absorbable, antibiotic-eluting envelope implanted when implanting cardiac devices like pacemakers and defibrillators can cut the rate of major infections by 40 percent.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE